<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964259</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18-14244</org_study_id>
    <secondary_id>NCI-2019-03468</secondary_id>
    <nct_id>NCT03964259</nct_id>
  </id_info>
  <brief_title>Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Pilot Study on the Reduced Intravenous Fluids to Improve Clearance of High-Dose Methotrexate (HDMTX) in Children With Lymphoma or Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether a reduced volume hydration regimen will lead to a shorter time to
      methotrexate clearance when compared to a standard intravenous (IV) hydration regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses a prospective randomized controlled crossover study design. Neither patients
      nor clinicians are blinded to the standard versus reduced intravenous fluids (IVF) regimen.
      Patients are randomized to begin with standard volume or reduced volume IVF. Over the course
      of 4 cycles of High Dose Methotrexate (HDMTX), patients alternate between standard and
      reduced volume post hydration fluids protocols.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study uses a prospective randomized controlled crossover study design.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time elapsed (in hours) from end of HDMTX to a serum methotrexate level &lt;0.1 micromol/L</measure>
    <time_frame>63 Days</time_frame>
    <description>To determine whether a reduced volume hydration regimen will lead to a shorter time to methotrexate clearance when compared to a standard IV hydration regimen by measuring serum methotrexate levels twenty-four hours following the end of the high dose methotrexate ( HDMTX) infusion, and continuing every twelve hours until the methotrexate level is less than 0.1 micromol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of kidney toxicity</measure>
    <time_frame>84 Days</time_frame>
    <description>To determine the effect of a reduced volume hydration regimen on markers of kidney toxicity (nephrotoxicity) by evaluating serum creatinine levels from baseline levels as well as the maximum decrease in estimated glomerular filtration rate (GFR) utilizing the modified Schwartz equation, following each HDMTX cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of fluid overload</measure>
    <time_frame>84 Days</time_frame>
    <description>To determine the effect of a reduced volume hydration regimen on markers of fluid overload by evaluating maximum weight gain during each hospitalization, and by evaluating the incidence of NCI Common Terminology Criteria for Adverse Events (CTCAE) version v5.0 ≥ grade 1 clinical sequelae of hydration such as facial edema, pulmonary edema, abdominal distension, extremity edema, and weight gain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on therapy delays</measure>
    <time_frame>84 Days</time_frame>
    <description>To examine the effects of a reduced volume hydration regimen on treatment schedule by measuring the number of days subsequent therapy is delayed for reasons other than scheduling issues or preferences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on development of severe mucositis</measure>
    <time_frame>84 Days</time_frame>
    <description>To examine the effects of a reduced volume hydration regimen on development of severe mucositis by measuring the incidence of grade ≥ 3 (CTCAE v5.0) mucositis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Lymphoma</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Pediatric Cancer</condition>
  <condition>Pediatric ALL</condition>
  <condition>Pediatric Lymphoma</condition>
  <arm_group>
    <arm_group_label>Standard Hydration Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the standard intravenous fluid (IVF) protocol, following completion of HDMTX infusion, post HDMTX IVF will be initiated at 125 mL/m2/hr (no maximum mL/hr total rate).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced hydration regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The reduced intravenous fluid (IVF) protocol, post HDMTX IVF will be initiated at 62.5 mL/m2/hr following completion of HDMTX infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous fluids</intervention_name>
    <description>Administration of post HDMTX intravenous fluids (IVF)</description>
    <arm_group_label>Reduced hydration regimen</arm_group_label>
    <arm_group_label>Standard Hydration Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of lymphoma or acute lymphoblastic leukemia

          -  Candidate for a minimum of 2 cycles HDMTX (5 g/m2) in the inpatient setting

          -  Creatinine clearance ≥ 65 mL/min by modified Schwartz equation

          -  Patients of childbearing potential must have a negative pregnancy test (serum or
             urine)

          -  Lactating female patients must agree not to nurse a child while on this trial

          -  All patients and/or their parents or legal guardians must provide written informed
             consent, with assent provided if applicable

        Exclusion Criteria:

          -  Trisomy 21

          -  History of dialysis within 30 days prior to study registration or currently on
             dialysis

          -  Polyuric renal dysfunction

          -  Pregnancy

          -  Known or suspected pleural effusion

          -  Medical, psychological, or social condition that, in the opinion of the investigator,
             may increase the patient's risk or limit the patient's adherence with study
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cady P Noda, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cady P Noda, Pharm.D.</last_name>
    <phone>804-828-4070</phone>
    <email>cady.noda@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsey B Gwaltney, RN</last_name>
    <phone>804-628-2112</phone>
    <email>lbgwaltney@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University/ Massey Cancer Center/ Children's Hospital of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey B Gwaltney, RN</last_name>
      <phone>804-628-2112</phone>
      <email>lbgwaltney@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cady P Noda, Pharm.D.</last_name>
      <phone>804-828-4070</phone>
      <email>cady.noda@vcuhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Cady P Noda, Pharm.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Dose Methotrexate</keyword>
  <keyword>HDMTX</keyword>
  <keyword>Intravenous Fluids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

